• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

基于美登素类和奥瑞他汀类抗体药物偶联物的物理特性比较

Physical characteristics comparison between maytansinoid-based and auristatin-based antibody-drug conjugates.

作者信息

Fujii Tomohiro, Reiling Calliste, Quinn Colette, Kliman Michal, Mendelsohn Brian A, Matsuda Yutaka

机构信息

Ajinomoto Bio-Pharma Services, 11040 Roselle Street, San Diego, CA 92121, United States.

TA Instruments, 159 Lukens Drive, New Castle, DE 19720, United States.

出版信息

Explor Target Antitumor Ther. 2021;2(6):576-585. doi: 10.37349/etat.2021.00064. Epub 2021 Dec 31.

DOI:10.37349/etat.2021.00064
PMID:36046112
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9400747/
Abstract

AIM

Direct analytical comparison of two major drug-linkers in the antibody-drug conjugate (ADC) field was conducted.

METHODS

Four different analytical methods [AlogP calculation, reverse phase (RP) high-performance liquid chromatography (HPLC; RP-HPLC), size exclusion chromatography HPLC (SEC-HPLC), and differential scanning calorimetry (DSC)] were tested for this comparison.

RESULTS

Maytansinoid-based ADCs showed less hydrophobicity than auristatin-based ADCs. Regardless of the drug-linker and drug-to-antibody ratios (DARs), the stability detected by DSC was decreased by conjugation.

CONCLUSIONS

The cost and time-efficient analytical comparison described in this manuscript may be useful information for an initial characterization of ADCs prior to detailed biological studies.

摘要

目的

对抗体药物偶联物（ADC）领域的两种主要药物连接子进行直接分析比较。

方法

为此比较测试了四种不同的分析方法[LogP计算、反相（RP）高效液相色谱（HPLC；RP-HPLC）、尺寸排阻色谱HPLC（SEC-HPLC）和差示扫描量热法（DSC）]。

结果

基于美登素的ADC比基于奥瑞他汀的ADC疏水性更低。无论药物连接子和药物与抗体比率（DAR）如何，通过DSC检测到的稳定性因偶联而降低。

结论

本手稿中描述的成本效益高且省时的分析比较可能是在进行详细生物学研究之前对ADC进行初步表征的有用信息。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/22c8/9400747/324c4d769e2a/etat-02-100264-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/22c8/9400747/a3973bb4a487/etat-02-100264-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/22c8/9400747/324c4d769e2a/etat-02-100264-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/22c8/9400747/a3973bb4a487/etat-02-100264-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/22c8/9400747/324c4d769e2a/etat-02-100264-g002.jpg

相似文献

1
Physical characteristics comparison between maytansinoid-based and auristatin-based antibody-drug conjugates.基于美登素类和奥瑞他汀类抗体药物偶联物的物理特性比较
Explor Target Antitumor Ther. 2021;2(6):576-585. doi: 10.37349/etat.2021.00064. Epub 2021 Dec 31.
2
Sensitive ELISA Method for the Measurement of Catabolites of Antibody-Drug Conjugates (ADCs) in Target Cancer Cells.用于检测靶癌细胞中抗体药物偶联物（ADC）代谢产物的灵敏酶联免疫吸附测定法。
Mol Pharm. 2015 Jun 1;12(6):1752-61. doi: 10.1021/acs.molpharmaceut.5b00028. Epub 2015 Mar 17.
3
Characterization of cysteine-linked conjugation profiles of immunoglobulin G1 and immunoglobulin G2 antibody-drug conjugates.免疫球蛋白G1和免疫球蛋白G2抗体-药物偶联物的半胱氨酸连接缀合谱的表征
J Pharm Sci. 2015 Apr;104(4):1362-72. doi: 10.1002/jps.24338. Epub 2015 Jan 28.
4
Effect of Linker-Drug Properties and Conjugation Site on the Physical Stability of ADCs.连接子-药物性质和连接点对 ADC 物理稳定性的影响。
J Pharm Sci. 2020 May;109(5):1662-1672. doi: 10.1016/j.xphs.2020.01.029. Epub 2020 Feb 4.
5
A size exclusion-reversed phase two dimensional-liquid chromatography methodology for stability and small molecule related species in antibody drug conjugates.一种用于抗体药物偶联物稳定性及小分子相关物质分析的尺寸排阻-反相二维液相色谱方法。
J Chromatogr A. 2015 May 8;1393:81-8. doi: 10.1016/j.chroma.2015.03.027. Epub 2015 Mar 16.
6
UPLC-based assay to assess the hydrophobicity of Antibody-Drug Conjugate (ADC) payloads.基于 UPLC 的抗体药物偶联物（ADC）有效载荷疏水性分析方法。
J Chromatogr B Analyt Technol Biomed Life Sci. 2020 Jun 1;1146:122075. doi: 10.1016/j.jchromb.2020.122075. Epub 2020 Mar 31.
7
Effects of Drug-Antibody Ratio on Pharmacokinetics, Biodistribution, Efficacy, and Tolerability of Antibody-Maytansinoid Conjugates.药物-抗体比例对抗体-美登素类偶联物药代动力学、生物分布、疗效和耐受性的影响
Bioconjug Chem. 2017 May 17;28(5):1371-1381. doi: 10.1021/acs.bioconjchem.7b00062. Epub 2017 Apr 13.
8
Evaluating the Potential of Cyclodextrins in Reducing Aggregation of Antibody-Drug Conjugates with Different Payloads.评估环糊精降低不同载药量抗体药物偶联物聚集的潜力。
J Pharm Sci. 2024 Aug;113(8):2443-2453. doi: 10.1016/j.xphs.2024.04.024. Epub 2024 Apr 26.
9
An Innovative Site-Specific Anti-HER2 Antibody-Drug Conjugate with High Homogeneity and Improved Therapeutic Index.一种具有高均一性和改善治疗指数的创新型位点特异性抗HER2抗体药物偶联物。
Onco Targets Ther. 2022 Apr 8;15:331-343. doi: 10.2147/OTT.S357326. eCollection 2022.
10
Auristatin antibody drug conjugate physical instability and the role of drug payload.奥瑞他汀抗体药物偶联物的物理不稳定性及药物有效载荷的作用。
Bioconjug Chem. 2014 Apr 16;25(4):656-64. doi: 10.1021/bc400439x. Epub 2014 Mar 13.

引用本文的文献

1
A Review on the Stability Challenges of Advanced Biologic Therapeutics.先进生物治疗药物稳定性挑战综述
Pharmaceutics. 2025 Apr 23;17(5):550. doi: 10.3390/pharmaceutics17050550.
2
Maytansinoids in cancer therapy: advancements in antibody-drug conjugates and nanotechnology-enhanced drug delivery systems.美登素类药物在癌症治疗中的应用：抗体-药物偶联物及纳米技术增强药物递送系统的进展
Discov Oncol. 2025 Jan 21;16(1):73. doi: 10.1007/s12672-025-01820-z.
3
Exo-Cleavable Linkers: Enhanced Stability and Therapeutic Efficacy in Antibody-Drug Conjugates.

本文引用的文献

1
Antibody-drug conjugates as targeted therapies: Are we there yet? A critical review of the current clinical landscape.抗体药物偶联物作为靶向治疗药物：我们已经做到了吗？对当前临床现状的批判性评价。
Drug Discov Today Technol. 2020 Dec;37:13-22. doi: 10.1016/j.ddtec.2020.07.002. Epub 2020 Sep 29.
2
Recent Advances in Drug-Antibody Ratio Determination of Antibody-Drug Conjugates.抗体药物偶联物的药物抗体比测定的最新进展。
Chem Pharm Bull (Tokyo). 2021;69(10):976-983. doi: 10.1248/cpb.c21-00258.
3
Chemical Site-Specific Conjugation Platform to Improve the Pharmacokinetics and Therapeutic Index of Antibody-Drug Conjugates.
可切割连接子：提高抗体药物偶联物的稳定性和治疗效果。
J Med Chem. 2024 Oct 24;67(20):18124-18138. doi: 10.1021/acs.jmedchem.4c01251. Epub 2024 Oct 15.
4
Tag-free protein modification by lipoate ligase A: exploring substrate tolerance.无标签蛋白修饰的脂酰基辅酶 A 连接酶 A：探索底物耐受性。
Anal Sci. 2024 Jun;40(6):1111-1119. doi: 10.1007/s44211-024-00534-6. Epub 2024 Mar 19.
5
Bispecific Antibodies Produced via Chemical Site-Specific Conjugation Technology: AJICAP Second-Generation.通过化学位点特异性偶联技术制备的双特异性抗体：AJICAP第二代
ACS Med Chem Lett. 2023 Nov 21;14(12):1767-1773. doi: 10.1021/acsmedchemlett.3c00414. eCollection 2023 Dec 14.
6
AJICAP Second Generation: Improved Chemical Site-Specific Conjugation Technology for Antibody-Drug Conjugate Production.AJICAP第二代：用于抗体药物偶联物生产的改进型化学位点特异性偶联技术。
Bioconjug Chem. 2023 Mar 9;34(4):728-38. doi: 10.1021/acs.bioconjchem.3c00040.
7
Enzymatic glycan remodeling-metal free click (GlycoConnect™) provides homogenous antibody-drug conjugates with improved stability and therapeutic index without sequence engineering.酶糖基重塑-无金属点击（GlycoConnectTM）提供了均一的抗体药物偶联物，无需序列工程即可提高稳定性和治疗指数。
MAbs. 2022 Jan-Dec;14(1):2078466. doi: 10.1080/19420862.2022.2078466.
化学定点偶联平台提高抗体药物偶联物的药代动力学和治疗指数。
Mol Pharm. 2021 Nov 1;18(11):4058-4066. doi: 10.1021/acs.molpharmaceut.1c00473. Epub 2021 Sep 27.
4
Lipoate-acid ligase a modification of native antibody: Synthesis and conjugation site analysis.脂肪酰基辅酶 A 连接酶对天然抗体的修饰：合成及连接点分析。
Bioorg Med Chem Lett. 2021 Nov 1;51:128360. doi: 10.1016/j.bmcl.2021.128360. Epub 2021 Sep 16.
5
Current approaches for the purification of antibody-drug conjugates.抗体药物偶联物的现行纯化方法。
J Sep Sci. 2022 Jan;45(1):27-37. doi: 10.1002/jssc.202100575. Epub 2021 Sep 16.
6
Stepping forward in antibody-drug conjugate development.抗体偶联药物开发的新进展。
Pharmacol Ther. 2022 Jan;229:107917. doi: 10.1016/j.pharmthera.2021.107917. Epub 2021 Jun 24.
7
Chromatographic analysis of site-specific antibody-drug conjugates produced by AJICAP first-generation technology using a recombinant FcγIIIa receptor-ligand affinity column.使用重组FcγIIIa受体-配体亲和柱对由AJICAP第一代技术生产的位点特异性抗体-药物偶联物进行色谱分析。
J Chromatogr B Analyt Technol Biomed Life Sci. 2021 Jul 1;1177:122753. doi: 10.1016/j.jchromb.2021.122753. Epub 2021 May 19.
8
Natural Product Based Antibody Drug Conjugates: Clinical Status as of November 9, 2020.基于天然产物的抗体药物偶联物：截至2020年11月9日的临床状况
J Nat Prod. 2021 Mar 26;84(3):917-931. doi: 10.1021/acs.jnatprod.1c00065. Epub 2021 Feb 26.
9
In-situ Reverse Phased HPLC Analysis of Intact Antibody-Drug Conjugates.原位反相高效液相色谱法分析完整抗体药物偶联物。
Anal Sci. 2021 Aug 10;37(8):1171-1176. doi: 10.2116/analsci.20P424. Epub 2021 Jan 29.
10
An overview of process development for antibody-drug conjugates produced by chemical conjugation technology.化学偶联技术制备抗体药物偶联物的工艺开发概述。
Expert Opin Biol Ther. 2021 Jul;21(7):963-975. doi: 10.1080/14712598.2021.1846714. Epub 2020 Dec 1.